|
1
|
Cancer Genome Atlas Research Network.
Comprehensive molecular characterization of gastric adenocarcinoma.
Nature. 513:202–209. 2014.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Gong Z, Mu Y, Chen J, Chu H, Lian P, Wang
C, Wang J and Jiang L: Expression and significance of cyclophilin J
in primary gastric adenocarcinoma. Anticancer Res. 37:4475–4481.
2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Wadhwa R, Song S, Lee JS, Yao Y, Wei Q and
Ajani JA: Gastric cancer-molecular and clinical dimensions. Nat Rev
Clin Oncol. 10:643–655. 2013.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
McGuire S: World Cancer Report 2014
Geneva, Switzerland: World Health Organization, International
Agency for Research on Cancer, WHO Press, 2015. Adv Nutr.
7:418–419. 2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Graziosi L, Marino E and Donini A:
Minimally invasive surgery for advanced gastric cancer: Are we
sure? Gastric Cancer. 20:1013–1014. 2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Peddanna N, Holt S and Verma RS: Genetics
of gastric cancer. Anticancer Res. 15:2055–2064. 1995.PubMed/NCBI
|
|
8
|
Lv Y, Zhao Y, Wang X, Chen N, Mao F, Teng
Y, Wang T, Peng L, Zhang J, Cheng P, et al: Increased intratumoral
mast cells foster immune suppression and gastric cancer progression
through TNF-α-PD-L1 pathway. J Immunother Cancer.
7(54)2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Xie Y, Li F, Li Z and Shi Z: miR-135a
suppresses migration of gastric cancer cells by targeting
TRAF5-mediated NF-κB activation. Onco Targets Ther. 12:975–984.
2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Deptala A, Bedner E, Gorczyca W and
Darzynkiewicz Z: Activation of nuclear factor kappa B (NF-kappaB)
assayed by laser scanning cytometry (LSC). Cytometry. 33:376–382.
1998.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Han F, Zhang L, Qiu W and Yi X: TRAF6
promotes the invasion and metastasis and predicts a poor prognosis
in gastric cancer. Pathol Res Pract. 212:31–37. 2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Inoue J, Gohda J and Akiyama T:
Characteristics and biological functions of TRAF6. Adv Exp Med
Biol. 597:72–79. 2007.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Sun YS, Ye ZY, Qian ZY, Xu XD and Hu JF:
Expression of TRAF6 and ubiquitin mRNA in skeletal muscle of
gastric cancer patients. J Exp Clin Cancer Res.
31(81)2012.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Maeda S, Yoshida H, Ogura K, Mitsuno Y,
Hirata Y, Yamaji Y, Akanuma M, Shiratori Y and Omata M: H.
pylori activates NF-kappaB through a signaling pathway
involving IkappaB kinases, NF-kappaB-inducing kinase, TRAF2, and
TRAF6 in gastric cancer cells. Gastroenterology. 119:97–108.
2000.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Takeuchi O and Akira S: Innate immunity to
virus infection. Immun Rev. 227:75–86. 2009.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Allen IC, Moore CB, Schneider M, Lei Y,
Davis BK, Scull MA, Gris D, Roney KE, Zimmermann AG, Bowzard JB, et
al: NLRX1 protein attenuates inflammatory responses to infection by
interfering with the RIG-I-MAVS and TRAF6-NF-κB signaling pathways.
Immunity. 34:854–865. 2011.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Moore CB, Bergstralh DT, Duncan JA, Lei Y,
Morrison TE, Zimmermann AG, Accavitti-Loper MA, Madden VJ, Sun L,
Ye Z, et al: NLRX1 is a regulator of mitochondrial antiviral
immunity. Nature. 451:573–577. 2008.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Coutermarsh-Ott S, Simmons A, Capria V,
LeRoith T, Wilson JE, Heid B, Philipson CW, Qin Q,
Hontecillas-Magarzo R, Bassaganya-Riera J, et al: NLRX1 suppresses
tumorigenesis and attenuates histiocytic sarcoma through the
negative regulation of NF-κB signaling. Oncotarget. 7:33096–33110.
2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Hu B, Ding GY, Fu PY, Zhu XD, Ji Y, Shi
GM, Shen YH, Cai JB, Yang Z, Zhou J, et al: NOD-like receptor X1
functions as a tumor suppressor by inhibiting
epithelial-mesenchymal transition and inducing aging in
hepatocellular carcinoma cells. J Hematol Oncol.
11(28)2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Fléjou JF: WHO Classification of digestive
tumors: The fourth edition. Ann Pathol. 31 (5 Suppl):S27–S31.
2011.PubMed/NCBI View Article : Google Scholar : (In French).
|
|
21
|
Zheng M, Zang S, Xie L, Fang X, Zhang YU,
Ma X, Liu J, Lin D and Huang A: Rheb phosphorylation is involved in
p38-regulated/activated protein kinase-mediated tumor suppression
in liver cancer. Oncol Lett. 10:1655–1661. 2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Lyros O, Thomaidis T, Muller M, Sivanathan
V, Grimminger P, Lang H, Gockel I, Hartmann JT and Moehler M:
External Validation of the Proposed Kiel Staging System and
Comparison with the Old (6th edition) and the Currently Used (7th
edition) TNM Classification in Gastric Cancer. Oncol Res Treat.
41:122–128. 2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Harino Y, Imura S, Kanemura H, Morine Y,
Fujii M, Ikegami T, Uehara H and Shimada M: Role of tumor
angiogenesis in gallbladder carcinoma: With special reference to
thymidine phosphorylase. Int J Clin Oncol. 13:452–457.
2008.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Bertuccio P, Chatenoud L, Levi F, Praud D,
Ferlay J, Negri E, Malvezzi M and La Vecchia C: Recent patterns in
gastric cancer: A global overview. Int J Cancer. 125:666–673.
2009.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Wang FH, Shen L, Li J, Zhou ZW, Liang H,
Zhang XT, Tang L, Xin Y, Jin J, Zhang YJ, et al: The Chinese
society of clinical oncology (CSCO): Clinical guidelines for the
diagnosis and treatment of gastric cancer. Cancer Commun (Lond).
39(10)2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Makino Y, Nishimura Y, Oshita S, Mizosoe T
and Akihiro T: Storage in high-barrier pouches increases the
sulforaphane concentration in broccoli florets. PLoS One.
13(e0192342)2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Chen W, Sun K, Zheng R, Zeng H, Zhang S,
Xia C, Yang Z, Li H, Zou X and He J: Cancer incidence and mortality
in China, 2014. Chin J Cancer Res. 30:1–12. 2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Ma D, Zhao Y, She J, Zhu Y, Zhao Y, Liu L
and Zhang Y: NLRX1 alleviates lipopolysaccharide-induced apoptosis
and inflammation in chondrocytes by suppressing the activation of
NF-κB signaling. Int Immunopharmacol. 71:7–13. 2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Scantlebery AML, Uil M, Butter LM, Poelman
R, Claessen N, Girardin SE, Florquin S, Roelofs JJTH and Leemans
JC: NLRX1 does not play a role in diabetes nor the development of
diabetic nephropathy induced by multiple low doses of
streptozotocin. PLoS One. 14(e0214437)2019.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Soares F, Tattoli I, Rahman MA, Robertson
SJ, Belcheva A, Liu D, Streutker C, Winer S, Winer DA, Martin A, et
al: The mitochondrial protein NLRX1 controls the balance between
extrinsic and intrinsic apoptosis. J Biol Chem. 289:19317–19330.
2014.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Tattoli I, Killackey SA, Foerster EG,
Molinaro R, Maisonneuve C, Rahman MA, Winer S, Winer DA, Streutker
CJ, Philpott DJ and Girardin SE: NLRX1 acts as an
epithelial-intrinsic tumor suppressor through the modulation of
TNF-mediated proliferation. Cell Rep. 14:2576–2586. 2016.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Wang X, Yang C, Liao X, Han C, Yu T, Huang
K, Yu L, Qin W, Zhu G, Su H, et al: NLRC and NLRX gene family mRNA
expression and prognostic value in hepatocellular carcinoma. Cancer
Med. 6:2660–2672. 2017.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Castaño-Rodríguez N, Kaakoush NO, Goh KL,
Fock KM and Mitchell HM: The NOD-like receptor signalling pathway
in Helicobacter pylori infection and related gastric cancer:
A case-control study and gene expression analyses. PLoS One.
9(e98899)2014.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Singh K, Poteryakhina A, Zheltukhin A,
Bhatelia K, Prajapati P, Sripada L, Tomar D and Singh R, Singh AK,
Chumakov PM and Singh R: NLRX1 acts as tumor suppressor by
regulating TNF-α induced apoptosis and metabolism in cancer cells.
Biochim Biophys Acta. 1853:1073–1086. 2015.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Zhang M, Pan L, Xu D, Cao C, Shi R, Han S,
Liu J, Li X and Li M: The NFκB signaling pathway serves an
important regulatory role in Klebsiella pneumoniae liver abscesses.
Exp Ther Med. 15:5443–5449. 2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Ahmmed B, Khan MN, Nisar MA, Kampo S,
Zheng Q, Li Y and Yan Q: Tunicamycin enhances the suppressive
effects of cisplatin on lung cancer growth through PTX3
glycosylation via AKT/NF-κB signaling pathway. Int J Oncol.
54:431–442. 2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Bishop RT, Marino S, de Ridder D, Allen
RJ, Lefley DV, Sims AH, Wang N, Ottewell PD and Idris AI:
Pharmacological inhibition of the IKKε/TBK-1 axis potentiates the
anti-tumour and anti-metastatic effects of Docetaxel in mouse
models of breast cancer. Cancer Lett. 450:76–87. 2019.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Marino S, Bishop RT, Carrasco G, Logan JG,
Li B and Idris AI: Pharmacological inhibition of NFκB reduces
prostate cancer related osteoclastogenesis in vitro and osteolysis
ex vivo. Calcif Tissue Int. 105:193–204. 2019.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Fu J, Yu L, Luo J, Huo R and Zhu B:
Paeonol induces the apoptosis of the SGC-7901 gastric cancer cell
line by downregulating ERBB2 and inhibiting the NF-κB signaling
pathway. Int J Mol Med. 42:1473–1483. 2018.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Novack DV: Role of NF-κB in the skeleton.
Cell Res. 21:169–182. 2011.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Jeong Y, Lim JW and Kim H: Lycopene
inhibits reactive oxygen species-mediated NF-κB signaling and
induces apoptosis in pancreatic cancer cells. Nutrients.
11(762)2019.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Li T, Li M, Xu C, Xu X, Ding J, Cheng L
and Ou R: miR-146a regulates the function of Th17 cell
differentiation to modulate cervical cancer cell growth and
apoptosis through NF-κB signaling by targeting TRAF6. Oncol Rep.
41:2897–2908. 2019.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Morgan JJ, McAvera RM and Crawford LJ:
TRAF6 silencing attenuates multiple myeloma cell adhesion to bone
marrow stromal cells. Int J Mol Sci. 20(702)2019.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Xia X, Cui J, Wang HY, Zhu L, Matsueda S,
Wang Q, Yang X, Hong J, Songyang Z, Chen ZJ and Wang RF: NLRX1
negatively regulates TLR-induced NF-κB signaling by targeting TRAF6
and IKK. Immunity. 34:843–853. 2011.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Paik JH, Jang JY, Jeon YK, Kim WY, Kim TM,
Heo DS and Kim CW: MicroRNA-146a downregulates NFκB activity via
targeting TRAF6 and functions as a tumor suppressor having strong
prognostic implications in NK/T cell lymphoma. Clin Cancer Res.
17:4761–4771. 2011.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Yang WL, Wang J, Chan CH, Lee SW, Campos
AD, Lamothe B, Hur L, Grabiner BC, Lin X, Darnay BG and Lin HK: The
E3 ligase TRAF6 regulates Akt ubiquitination and activation.
Science. 325:1134–1138. 2009.PubMed/NCBI View Article : Google Scholar
|
